1 ILD) in a large cohort of patients with anti-Jo-1 antibodies.

2 A topoisomerase I), anticentromere, and anti-Jo-1 antibodies.

3 vealed a modest correlation between the anti-Jo-1 antibody level and the serum creatine kinase (CK) l

4       Further, there was a reduction in anti-Jo-1 antibody levels and a partial recovery of IgA (to 6

5  have examined the relationship between anti-Jo-1 antibody levels and myositis disease activity, demo

6 e used to identify associations between anti-Jo-1 antibody levels and organ-specific disease activity

7 cally reexamine the association between anti-Jo-1 antibody levels and various disease manifestations

8  with idiopathic inflammatory myopathy, anti-Jo-1 antibody levels correlated modestly with muscle and

9 ses of 11 patients with serial samples, anti-Jo-1 antibody levels correlated significantly with CK le

10 ngitudinal subset of patients that link anti-Jo-1 antibody levels to muscle, joint, lung, and global

11                                   Serum anti-Jo-1 antibody levels were quantified using 2 independent

12  and peripheral blood quantification of anti-Jo-1 antibody levels, lymphocyte subsets, immunoglobulin

13 ically significant associations between anti-Jo-1 antibody-positive ILD and elevated serum levels of

14 d disease-specific associations between anti-Jo-1 antibody-positive ILD and serum levels of CRP as we

15 sess the serum proteins associated with anti-Jo-1 antibody-positive ILD.

16 dies determined the existence of ILD in anti-Jo-1 antibody-positive individuals whose data were accum

17                            Among the 90 anti-Jo-1 antibody-positive individuals with sufficient clini

18                 In this large cohort of anti-Jo-1 antibody-positive individuals, the incidence of ILD

19 ectional assessment of 81 patients with anti-Jo-1 antibody revealed a modest correlation between the

20                                              Jo-1 antibody was present in 19 (38%) of 50 patients tes